Using this approach, we identified FLT3 as the dominant clone in six non-APL AML patients, followed by DNMT3A and TP53 in two patients each, and RUNX1, WT1, and NPM1 in one patient each. This evidence concerns the gene FLT3 and acute myeloid leukemia.